Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort

AETHLON MEDICAL INC

2026-Q1 EPS reported -$0.85

Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.
First cohort completed in Australian Hemopurifier cancer trial; DSMB approves second cohort with two treatments.
Amended protocol broadens eligibility to any anti-PD-1 regimen; preclinical data show 98.5% removal of platelet-derived EVs.
India oncology study dropped due to extended timeline; Long COVID research with UCSF presented at Keystone Symposium.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.